Dr. Reddy's Laboratories Launched Palonosetron Hydrochloride Injection in the U.S. Market Today

Monday, March 26, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Palonosetron Hydrochloride Injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent generic version of ALOXI® (palonosetron hydrochloride) Injection approved by the U.S. Food and Drug Administration (USFDA).

The ALOXI® brand and generic had U.S. sales of approximately $446 million MAT for the most recent twelve months ending in January 2018 according to IMS Health*.

Dr. Reddy’s Palonosetron Hydrochloride Injection is available in a strength of 0.25 mg/5 mL (free base) in a single-dose vial packaged in a carton containing one vial.

ALOXI® is a registered trademark of Helsinn Healthcare SA.

*IMS National Sales Perspective: Retail and Non-Retail MAT January 2018

RDY-0318-196
Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store